期刊
MINI-REVIEWS IN MEDICINAL CHEMISTRY
卷 15, 期 9, 页码 731-750出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557515666150521162237
关键词
Histone Deacetylase; cancer; isoform; Romidepsin; US-FDA
资金
- Council of Scientific and Industrial Research
- University Grant Commission
Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has summarized the inhibitors, based on their specificity towards different isoforms within this class. Further various recent United State (US) patents and the HDAC inhibitors, used singly or in combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据